Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

被引:713
|
作者
Herold, Tobias [1 ,2 ,6 ,7 ,8 ]
Jurinovic, Vindi [1 ,7 ,9 ]
Arnreich, Chiara [1 ,7 ]
Lipworth, Brian J. [10 ]
Hellmuth, Johannes C. [1 ,3 ]
von Bergwelt-Baildon, Michael [1 ,3 ,6 ,8 ,11 ]
Klein, Matthias [2 ,4 ]
Weinberger, Tobias [2 ,5 ,12 ]
机构
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Univ Hosp, Emergency Dept, Munich, Germany
[3] Ludwig Maximilians Univ Munchen, Univ Hosp, COVID 19 Registry LMU Munich CORKUM, Munich, Germany
[4] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Neurol, Munich, Germany
[5] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 1, Munich, Germany
[6] Nine I Network, Munich, Germany
[7] Helmholtz Zentrum Munchen, German Ctr Environm Hlth HMGU, Res Unit Apoptosis Hematopoiet Stem Cells, Munich, Germany
[8] German Canc Consortium DKTK, Partner Site Munich, Munich, Germany
[9] Ludwig Maximilians Univ Munchen, Inst Med Informat Proc Biometry & Epidemiol, Munich, Germany
[10] Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee, Scotland
[11] Intens Care Hematol & Oncol Patients iCHOP, Cologne, Germany
[12] German Ctr Cardiovasc Res DZHK, Partner Site Munich Heart Alliance, Munich, Germany
关键词
IL-6; CRP; COVID-19; respiratory failure; mechanical ventilation; prediction; hyperinflammation; INTERLEUKIN-6; REGULATOR; SEVERITY; CARE;
D O I
10.1016/j.jaci.2020.05.008
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Coronavirus disease 2019 (COVID-19) can manifest as a viral-induced hyperinflammation with multiorgan involvement. Such patients often experience rapid deterioration and need for mechanical ventilation. Currently, no prospectively validated biomarker of impending respiratory failure is available. Objective: We aimed to identify and prospectively validate biomarkers that allow the identification of patients in need of impending mechanical ventilation. Methods: Patients with COVID-19 who were hospitalized from February 29 to April 9, 2020, were analyzed for baseline clinical and laboratory findings at admission and during the disease. Data from 89 evaluable patients were available for the purpose of analysis comprising an initial evaluation cohort (n = 40) followed by a temporally separated validation cohort (n = 49). Results: We identified markers of inflammation, lactate dehydrogenase, and creatinine as the variables most predictive of respiratory failure in the evaluation cohort. Maximal IL-6 level before intubation showed the strongest association with the need for mechanical ventilation, followed by maximal CRP level. The respective AUC values for IL-6 and CRP levels in the evaluation cohort were 0.97 and 0.86, and they were similar in the validation cohort (0.90 and 0.83, respectively). The calculated optimal cutoff values during the course of disease from the evaluation cohort (IL-6 level > 80 pg/mL and CRP level > 97 mg/L) both correctly classified 80% of patients in the validation cohort regarding their risk of respiratory failure. Conclusion: The maximal level of IL-6, followed by CRP level, was highly predictive of the need for mechanical ventilation. This suggests the possibility of using IL-6 or CRP level to guide escalation of treatment in patients with COVID-19-related hyperinflammatory syndrome.
引用
收藏
页码:128 / +
页数:13
相关论文
共 50 条
  • [31] Outlook of IL-6 signaling blockade for COVID-19 pneumonia
    Hashizume, Misato
    INFLAMMATION AND REGENERATION, 2020, 40 (01)
  • [32] Is IL-6 the Right Target in COVID-19 Severe Pneumonia?
    Blot, Mathieu
    Bourredjem, Abderrahmane
    Binquet, Christine
    Piroth, Lionel
    Quenot, Jean-Pierre
    Charles, Pierre-Emmanuel
    Aptel, Francois
    Prin, Sebastien
    Andreu, Pascal
    Labruyere, Marie
    Dargent, Auguste
    Nguyen, Maxime
    Bouhemad, Belaid
    Georges, Marjolaine
    Bonniaud, Philippe
    Beltramo, Guillaume
    Buisson, Marielle
    Bonnotte, Bernard
    Bielefeld, Philip
    Barben, Jeremy
    Putot, Alain
    Monier, Serge
    Large, Audrey
    Mouries-Martin, Suzanne
    Devilliers, Herve
    Chavanet, Pascal
    Guilhem, Alexandre
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (01) : 139 - 140
  • [33] IL-6 and other biomarkers as predictors of severity in COVID-19
    Broman, N.
    Rantasarkka, K.
    Feuth, T.
    Valtonen, M.
    Waris, M.
    Hohenthal, U.
    Rintala, E.
    Karlsson, A.
    Marttila, H.
    Peltola, V.
    Vuorinen, T.
    Oksi, J.
    ANNALS OF MEDICINE, 2021, 53 (01) : 410 - 412
  • [34] Outlook of IL-6 signaling blockade for COVID-19 pneumonia
    Misato Hashizume
    Inflammation and Regeneration, 40
  • [35] Usage of IL-6 antagonists in COVID-19: A challenge in children
    Niu, Man Man
    Fan, Guo Zhen
    Li, Rui Xue
    Jiang, Qi
    Hu, Peng
    RESPIROLOGY, 2022, 27 (03) : 245 - 245
  • [36] PHARMACEUTICALS IL-6 blockers tested against COVID-19
    Jarvis, Lisa M.
    CHEMICAL & ENGINEERING NEWS, 2020, 98 (11) : 13 - 13
  • [37] Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling
    Zizzo, Gaetano
    Tamburello, Antonio
    Castelnovo, Laura
    Laria, Antonella
    Mumoli, Nicola
    Faggioli, Paola Maria
    Stefani, Ilario
    Mazzone, Antonino
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [38] Antirheumatic agents in covid-19: is IL-6 the right target?
    Capecchi, Pier Leopoldo
    Lazzerini, Pietro Enea
    Volterrani, Luca
    Mazzei, Maria Antonietta
    Rossetti, Barbara
    Zanelli, Giacomo
    Bennett, David
    Bargagli, Elena
    Franchi, Federico
    Cameli, Matteo
    Valente, Serafina
    Cantarini, Luca
    Frediani, Bruno
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (01)
  • [39] The role of vitamin D receptor and IL-6 in COVID-19
    Azmi, Ali
    Rismani, Maziyar
    Pourmontaseri, Hossein
    Mirzaii, Ebrahim
    Niknia, Sedigheh
    Miladpour, Behnoosh
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2023, 11 (07):
  • [40] Is IL-6 a key cytokine target for therapy in COVID-19?
    Simon A. Jones
    Christopher A. Hunter
    Nature Reviews Immunology, 2021, 21 : 337 - 339